19 September 2019 
EMA/504760/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Trulicity 
dulaglutide 
On 19 September 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Trulicity. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.. 
The CHMP adopted a change to the existing indication as follows:2  
“Type 2 Diabetes Mellitus 
Trulicity is indicated for the treatment of in adults with insufficiently controlled type 2 diabetes mellitus 
as an adjunct to diet and exercise improve glycaemic control as: 
• 
• 
As Mmonotherapy Wwhen diet and exercise alone do not provide adequate glycaemic control in 
patients for whom the use of metformin is considered inappropriate due to intolerance or 
contraindications 
In addition to other Add-on therapy  In combination with other glucose-lowering medicinal products 
for the treatment of diabetes. including insulin, when these, together with diet and exercise, do not 
provide adequate glycaemic control (see section 5.1 for data with respect to different combinations). 
For study results with respect to combinations, effects on glycaemic control and cardiovascular 
events, and the populations studied, see sections 4.4, 4.5 and 5.1.”  
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
 
 
 
 
 
                                                
